Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
- DOI
- 10.1016/j.ejca.2024.115192
- Published
- 2025 Feb 25
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2024.115192,
title = {Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.},
author = {Dennis N and Dunton K and Livings C and Bogoeva N and Bourke S and Oluboyede Y and Hamilton E and Iwata H and Cortés J},
year = {2025},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2024.115192},
url = {https://doi.org/10.1016/j.ejca.2024.115192}
}RIS
TY - JOUR TI - Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. AU - Dennis N AU - Dunton K AU - Livings C AU - Bogoeva N AU - Bourke S AU - Oluboyede Y AU - Hamilton E AU - Iwata H AU - Cortés J PY - 2025 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2024.115192 UR - https://doi.org/10.1016/j.ejca.2024.115192 ER -
APA
N, D., K, D., C, L., N, B., S, B., Y, O., E, H., H, I., & J, C. (2025). Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2024.115192
Source records
- pubmed · retrieved 2026-09-25T17:10:26.143Z